News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Avastin as Good as Novartis AG (NVS)'s Lucentis for AMD


7/19/2013 7:44:44 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Published in the Lancet on Friday, a trial has been claiming that the NHS should make use of an unlicensed drug, cheaper than the licensed one, to treat people at risk of going blind. Since, the same could help it save almost £84m or more each year. It was being questioned if Avastin, the cancer drug, was safe to cure people suffering from wet age-related macular degeneration (AMD).

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at News Release
Read at Belfast Telegraph
Read at News Release


comments powered by Disqus
Roche
Novartis AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES